MOLECULAR PARTNERS AG (MOLN): Price and Financial Metrics
GET POWR RATINGS... FREE!
MOLN Stock Price Chart Interactive Chart >
MOLN Price/Volume Stats
| Current price | $6.58 | 52-week high | $29.06 |
| Prev. close | $6.73 | 52-week low | $5.50 |
| Day low | $6.50 | Volume | 4,100 |
| Day high | $6.67 | Avg. volume | 1,924 |
| 50-day MA | $6.68 | Dividend yield | N/A |
| 200-day MA | $7.50 | Market Cap | 237.18M |
MOLECULAR PARTNERS AG (MOLN) Company Bio
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials.
Latest MOLN News From Around the Web
Below are the latest news stories about MOLECULAR PARTNERS AG that investors may wish to consider to help them evaluate MOLN as an investment opportunity.
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid LeukemiaZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announced today that the first patient has been treated in a Phase 1 first-in-human study evaluating the safety, tolerability, and efficacy of MP0533, the company’s candidate for acute myeloid leukemia (AML). MP0533 is designed to focus an immune attack against AML in a new way that preferentially spares healthy cells, which has been a historic challenge for CD3-targeting therapeutics. |
Molecular Partners starts early-stage study of blood cancer drug MP0533Molecular Partners (MOLN) said the first patient was treated in a phase 1 trial of its blood cancer drug MP0533.The study will enroll patients with relapsed/refractory acute… |
Hedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the companyA look at the shareholders of Molecular Partners AG ( VTX:MOLN ) can tell us which group is most powerful. With 41... |
Molecular Partners Provides Updates at 41st Annual JPM Healthcare ConferenceZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced several developments in its infectious disease and oncology portfolios. These include: DARPin Radioligand Therapy platform progressing well. Disclosure of the tumor-associated protein Delta- |
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor ConferencesZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcom |
MOLN Price Returns
| 1-mo | 5.28% |
| 3-mo | 4.82% |
| 6-mo | 6.30% |
| 1-year | -76.47% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 0.46% |
| 2022 | -65.85% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...